OrganonOGN -0.15%71 Receivables Turnover is 1.08 as of Mar. 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.54 (Fairly Valued). The stock has 10 warning signs investors should review. Among 946 Drug Manufacturers companies, Organon ranks worse than 61.63% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Organon's Revenue for the
three
months ended in Mar. 2026 was $1,460 Mil. Organon's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1,358 Mil.
Hence, Organon's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.08.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Organon Receivables Turnover Related Terms
Organon Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Organon's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OGN vs AMRN, SCLX, MIRA: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Organon's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Organon's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organon (OGN) has a Receivables Turnover of 1.08 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Organon and its competitors. According to the industry distribution chart, Organon ranks #583 out of 946 companies in the Drug Manufacturers industry, placing it in the top 61.6%.
Is Organon's Receivables Turnover too high?
Organon's current Receivables Turnover is 1.08. The Drug Manufacturers industry median Receivables Turnover is 5.07. Organon's value of 1.08 is 78.7% below this industry median. Based on the distribution chart, Organon ranks #583 out of 946 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Receivables Turnover compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #583 out of 946 companies for Receivables Turnover. This places Organon in the lower half of its industry. The industry median Receivables Turnover is 5.07. Organon's value of 1.08 is 78.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current Receivables Turnover of 1.08 is 78.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current Receivables Turnover is 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.54, compared to a current price of $13.54 — trading 6.9% below its estimated fair value. The current Receivables Turnover is 1.08 and 78.7% below the Drug Manufacturers industry median of 5.07. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Organon (OGN), the current Receivables Turnover is 1.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.54 is trading 6.9% below its estimated GF Value™ of $14.54.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Receivables Turnover: 1.08
GF Value™: $14.54 vs. price of $13.54 (6.9% below fair value)
Industry Position: 78.7% below the Drug Manufacturers median (#583 of 946)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
